what are peptides bpc 157 BPC-157 – No Proof Required! | Office for Science and Society BPC-157 FDA Approval Status: Is

Unlike conventional treatments that temporarily mask pain signals, peptide therapy aims to address the underlying biological processes driving the condition

When bruising is severe, recurrent, or accompanied by other signs such as mucosal bleeding (nosebleeds, gum bleeding), petechiae (tiny pinpoint red spots), or systemic symptoms, underlying medical conditions should be considered

For patients with neurological involvement, maintenance injections are typically given every 2 months

Raised IGF-1: levels are checked periodically, and the dose is adjusted if they climb too high

One of the most widely referenced regenerative peptides in preclinical biochemistry research

Reminder: Retatrutide remains investigational it is in Phase 3 trials (TRIUMPH program) and is not approved for human use as of 2026